Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for Treating Oncological Diseases

a technology for oncology and cancer cells, applied in the field of oncological diseases, can solve the problems of cancer cells becoming desensitized to the therapy, low efficacy, cell death, etc., and achieve the effect of low toxicity and high efficiency

Active Publication Date: 2013-08-15
CLS THERAPEUTICS
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0020]The blood's extracellular DNA in cancer patients contains a unique quantitative and qualitative repertoire of genes and regulating genetic elements which greatly differ from that of DNA in a healthy human genome. In contract to intracellular DNA, extracellular DNA in cancer patients mainly contains unique human genes, including genes which are involved in a development of and a maintenance of malignant behavior in cancer cells. Because blood's extracellular DNA contributes to malignant growth in cancer patients, a destruction of, a modification of, or a binding of blood's extracellular DNA is useful because it slows down that growth. These interventions are very useful in independent therapy and they also increase an effectiveness of traditional methods of treatment.

Problems solved by technology

The result of this drug's influence is an accumulation of double-stranded intracellular DNA breaks which lead to the cell's death.
A drawback of this method prototype, along with well-known methods, is their low efficacy.
Because of high genetic variability, these cancer cells become desensitized to the therapies before they are adequately eliminated.
A further disadvantage is that the intracellular DNA is a difficult-to-approach target; it leads to necessary high-dosing antineoplastic chemotherapy and / or other complicated delivery systems.
A final disadvantage to these methods is that they are highly toxic: their influence on cancerous cells' intracellular DNA also damages healthy cells' DNA.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

Inhibition of Erlich Carcinoma Growth

[0031]Recombinant human DNAase 1 (Genentech) was used.

[0032]1 group: 10 mice bearing Erlich carcinoma was used as control. The mice were injected with 0.2 ml of phosphate buffer intraperitoneally twice a day every day from day 3 to day 7 after the tumor cell transplantation.

[0033]2 group: 10 mice bearing Erlich carcinoma were introduced with intraperitoneal injections of DNAase in dose of 1 mg / kg of body weight in 0.2 ml of phosphate buffer four times daily every day from day 3 to day 7 after the tumor cell transplantation.

[0034]3 group: 10 mice bearing Erlich carcinoma were administered with intraperitoneal injections of DNAase in dose of 0.5 mg / kg of body weight in 0.2 ml of phosphate buffer four times daily every day from day 3 to day 7 after the tumor cell transplantation.

[0035]4 group: 10 mice bearing Erlich carcinoma were administered with intraperitoneal injections of DNAase in dose of 0.1 mg / kg of body weight in 0.2 ml of phosphate buffer...

example 2

Inhibition of Erlich Carcinoma Growth

[0040]Recombinant human DNAase 1 (Genentech) was used.

[0041]5groups of mice bearing LLC were used.

[0042]1 group - 7 mice - the control.

[0043]2 group - 6 mice were administered with intraperitoneal injections of DNAase in dose of 1 mg / kg of body weight twice a day every day from day 3 to day 5 after the tumor cell transplantation.

[0044]3 group - 6 mice were administered with intraperitoneal injections of DNAase in dose of 1 mg / kg of body weight twice a day every day from day 3 to day 10 after the tumor cell transplantation.

[0045]4 group - 6 mice were administered with intraperitoneal injections of DNAase in dose of 1 mg / kg of body weight twice a day every day from day 3 to day 15 after the tumor cell transplantation.

[0046]5 group - 6 mice were administered with intraperitoneal injections of DNAase in dose of 1 mg / kg of body weight twice a day every day from day 3 to day 18 after the tumor cell transplantation.

[0047]6 group - 6 mice were administer...

example 3

Lung Carcinoma Treatment

[0051]54-years-old man has been admitted to the hospital with diagnosis of lung carcinoma.

[0052]By patient's agreement, due to lack of any available treatment modality, subcutaneous injections of domaze-alpha were prescribed. The treatment began with administration of daily dose of 50 mkg / kg. Every consecutive day blood extracellular DNA level was measured and blood extracellular DNA was fractioned by electrophoresis. Once a week the primary tumor site and metastases were checked with X-rays and NMR-tomography. After initial 7 day period the domaze-alpha daily dose has been increased up to 100 mkg / kg because of no changes in level and electrophoresis pattern of blood extracellular DNA and no reactions from primary site of the tumor and the metastases. Because of no changes after another 7 days the dosing has been increased up to 150 mkg / kg. Two days after the first injection of the preparation in dose 150 mkg / kg the material recession (more than 50%) of the b...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
volumeaaaaaaaaaa
volumeaaaaaaaaaa
wavelengthaaaaaaaaaa
Login to View More

Abstract

A method to treat solid tumors and other oncological diseases consists of parenterally injecting an agent which destroy's blood's extracellular DNA into the systemic blood circulation of a cancer patient to slow down malignant. The agent is embodied in the form of a DNAse enzyme and, more particularly, as a bovine pancreatic DNAse. Doses from 50,000-250,000,000 Kunz units / day are injected for 5-360 days. A binding agent or an agent that modifies the chemical composition of the blood extracellular DNA is additionally injected into the blood. This modifying agent is preferably an enzyme-ribonuclease.

Description

RELATED APPLICATIONS[0001]The present invention is a Continuation in Part of U.S. Ser. No. 10 / 564861, filed on Jan. 12, 2006 and was a National Phase Filing of PCT / RU2004 / 00261. Additionally, the following copending applications are related to the present subject matter:[0002]1. U.S. Ser. No. 10 / 564,615 for “Method for treating oncological, virulent and somatic diseases, method for controlling treatment efficiency, pharmaceutical agents and compositions for carrying out said treatment”, filed on Jan. 12, 2006, which was a National Phase Filing of PCT / RU2003 / 000304;[0003]2. U.S. Ser. No. 10 / 564,609 for “Method for Treating Diseases Associated with Changes of Qualitative and Quantitative Composition of Blood Extracellular DNA”, filed on Jan. 12, 2006, which was a National Phase Filing of PCT / RU2004 / 00260; and[0004]3. U.S. Ser. No. 11 / 919,141 for “Method for retarding unhealthy manifestations brought by ageing of human beings”, filed on Oct. 23, 2007, which was a National Phase Filing ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61P35/00A61K38/46
CPCC12Y301/21003A61K38/465A61P35/00C12N9/22A61K38/00
Inventor GENKIN, DMITRY DMITRIEVICHTETS, VIKTOR VENIAMINOVICHTETS, GEORGY VIKTOROVICH
Owner CLS THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com